For the first time pembrolizumab, an anti-PD-1 monoclonal antibody, has been approved in cancer treatments that are based on the tumor biomarkers of high microsatellite instability or mismatch repair deficiency, regardless of the tumor’s original location (42). This evidence concerns the gene PDCD1 and neoplasm.